Pfizer Türkiye Announces Key Appointment

Ahmet Kumkumoğlu, who joined the Pfizer family in 2010 as Marketing Information Project Manager, has been appointed Pfizer Turkey Oncology Category Leader. Ahmet Kumkumoğlu graduated from the Mechatronics Engineering Department at Sabancı University in 2008 and completed his MBA at the same university in 2010. After joining Pfizer in 2010 as Marketing Information Project Manager and serving as Product Manager between 2012 and 2016, Kumkumoğlu took on the role of Market Access and Pricing Manager in September 2016. In July 2017, he assumed the Corporate Relations Leadership position. In this role, he led the development of Pfizer Turkey's corporate strategy and contributed to the formulation of healthcare policies in the country. [caption id="attachment_152435" align="aligncenter"] Ahmet Kumkumoğlu[/caption] Between December 2020 and September 2021, Ahmet Kumkumoğlu worked as Oncology Biosimilars and Marketing Excellence Leader, during which time he contributed to the development of Pfizer Turkey Oncology's 2023 vision. From September 2021 onwards, he has served as Internal Specialties Category Leader. Pfizer Turkey Oncology Category Leader Ahmet Kumkumoğlu commented on the matter as follows: "Working hand in hand with everyone fighting cancer; we are committed to delivering groundbreaking innovations that transform patients' lives and contributing to humanity's victory against the greatest health challenges through science. For us, there can be no more patient-focused, priority-driven and globally inclusive mission. With our innovative cancer and biosimilar solutions used in the treatment of 30 different types of cancer, we are focusing particularly on treating difficult and advanced cancer types. It excites us to be a part of hope by sharing the same mission with healthcare workers, physicians, patient associations, patients' families, the research-based pharmaceutical industry and every individual living with cancer in our country. I am proud to be part of this mission and of the Pfizer family, which is a leading institution.